Abstract:The two main pathological hallmarks of Parkinson's disease are loss of dopamine neurons in the substantia nigra pars compacta and proteinaceous amyloid fibrils composed mostly of α-synuclein, called Lewy pathology. Levodopa to enhance dopaminergic transmission remains one of the most effective treatment for alleviating the motor symptoms of Parkinson's disease (Olanow, Mov Disord 34:812-815, 2019). In addition, deep brain stimulation (Bronstein et al., Arch Neurol 68:165, 2011) to modulate basal ganglia circuit activity successfully alleviates some motor symptoms. MRI guided focused ultrasound in the subthalamic nucleus is a promising therapeutic strategy as well (Martinez-Fernandez et al., Lancet Neurol 17:54-63, 2018). However, to date, there exists no treatment that stops the progression of this disease. The findings that α-synuclein can be released from neurons and inherited through interconnected neural networks opened the door for discovering novel treatment strategies to prevent the formation and spread of Lewy pathology with the goal of halting PD in its tracks. This hypothesis is based on discoveries that pathologic aggregates of α-synuclein induce the endogenous α-synuclein protein to adopt a similar pathologic conformation, and is thus self-propagating. Phase I clinical trials are currently ongoing to test treatments such as immunotherapy to prevent the neuron to neuron spread of extracellular aggregates. Although tremendous progress has been made in understanding how Lewy pathology forms and spreads throughout the brain, cell intrinsic factors also play a critical role in the formation of pathologic α-synuclein, such as mechanisms that increase endogenous α-synuclein levels, selective expression profiles in distinct neuron subtypes, mutations and altered function of proteins involved in α-synuclein synthesis and degradation, and oxidative stress. Strategies that prevent the formation of pathologic α-synuclein should consider extracellular release and propagation, as well as neuron intrinsic mechanisms.

SUMOylation and ubiquitination reciprocally regulate α-synuclein degradation and pathological aggregation

Direct and/or Indirect Roles for SUMO in Modulating Alpha-Synuclein Toxicity

Oligomeric Α-Synuclein Inhibits Tubulin Polymerization

α-Synuclein ubiquitination – functions in proteostasis and development of Lewy bodies

SUMOylation Regulates TDP-43 Splicing Activity and Nucleocytoplasmic Distribution

Role of Ubiquitin–Proteasome and Autophagy-Lysosome Pathways in α-Synuclein Aggregate Clearance

Monitoring α-synuclein ubiquitination dynamics reveals key endosomal effectors mediating its trafficking and degradation

α-Synuclein Oligomers Displace Monomeric α-Synuclein from Lipid Membranes

SUMOylation at K340 inhibits tau degradation through deregulating its phosphorylation and ubiquitination

USP19 deubiquitinase inactivation regulates α-synuclein ubiquitination and inhibits accumulation of Lewy body-like aggregates in mice

Assembly of Lysine 63-Linked Ubiquitin Conjugates by Phosphorylated Α-Synuclein Implies Lewy Body Biogenesis

β-synuclein regulates the phase transitions and amyloid conversion of α-synuclein

[Potential Involvement of Abnormal Increased SUMO-1 in Modulation of the Formation of Alzheimer's Disease Senile Plaques and Neuritic Dystrophy in APP/PS1 Transgenic Mice].

Role of SUMOylation in Neurodegenerative Diseases

O-GlcNAcylation Inhibits the Oligomerization of Alpha-Synuclein by Declining Intermolecular Hydrogen Bonds Through a Steric Effect.

Initiation and propagation of α-synuclein aggregation in the nervous system

SUMOylation modulates mitochondrial dynamics in an in vitro rotenone model of Parkinson's disease

Broad proteomics analysis of seeding-induced aggregation of α-synuclein in M83 neurons reveals remodeling of proteostasis mechanisms that might contribute to Parkinson's disease pathogenesis

Molecular Behavior of α-Synuclein Is Associated with Membrane Transport, Lipid Metabolism, and Ubiquitin–Proteasome Pathways in Lewy Body Disease

Leucine Carboxyl Methyltransferase Downregulation and Protein Phosphatase Methylesterase Upregulation Contribute Toward the Inhibition of Protein Phosphatase 2A by α-Synuclein

Protein–protein interactions regulating α-synuclein pathology